Availability and use of non-prescribed buprenorphine-naloxone in a Canadian setting, 2014–2020

Original research
by
Bach, Paxton et al

Release Date

2022

Geography

Canada

Language of Resource

English

Full Text Available

No

Open Access / OK to Reproduce

No

Peer Reviewed

Yes

Objective

In Canada, restrictions on BUP-NX prescribing were relaxed in 2016, which may have had an effect on rates of diversion and non-prescribed use. We sought to longitudinally examine the reported availability and use of non-prescribed BUP-NX among people who use drugs (PWUD) in an urban Canadian setting.

Findings/Key points

We observed that BUP-NX has become increasingly available in the unregulated drug supply in recent years but its use has remained infrequent in this setting. These results suggest that relaxed restrictions on BUP-NX prescribing have not been a major driver of increased non-prescribed use in this population.

Design/methods

Two linked prospective cohorts (n=1617)

Keywords

Hesitancy of prescribers
About PWUD
Substitution/OAT
Diversion